Accumulation of frameshift mutations at genes containing coding mononucleotide repeats is thought to be the major molecular mechanism by which mismatch repair-deficient cells accumulate functional alterations. These mutations resulting from microsatellite instability (MSI) can affect genes involved in pathways with a putative oncogenic role, but may also arise in genes without any expected role in MSI carcinogenesis because of the high mutation background of these tumours. We here screened 39 MSI colorectal tumours for the presence of mutations in 25 genes involved in DNA damage signalling and repair pathways. Using a maximum likelihood statistical method, these genes were divided into two different groups that differed significantly in their mutation frequencies, and likely represent mutations that do or do not provide selective pressure during MSI tumour progression. Interestingly, the so-called real-target mutational events were found to be distributed among genes involved in different functional pathways of the DNA metabolism, for example, DNA damage signalling (DNA-PKcs, ATR), double-strand break (DSB) repair (DNA-PKcs, RAD50), mismatch repair (MSH3, MSH6, MBD4) and replication (POLD3). In particular, mutations in MRE11 and/or RAD50 were observed in the vast majority of the tumours and resulted in the concomitant loss of immunohistochemical expression of both proteins. These data might explain why MSI colorectal cancers (CRC) behave differently in response to a wide variety of chemotherapeutic agents, notably those targeting DNA. More generally, they give further insights into how MSI leads to functional changes with synergistic effects in oncogenic pathways.
Introduction
The instability of microsatellite repeated sequences in tumours underlies the hereditary non-polyposis colorectal cancer syndrome (HNPCC), which is frequently associated with a germline mutation in one of the mismatch repair (MMR) genes, predominantly MLH1 and MSH2 (Aaltonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993) . Apart from HNPCC, microsatellite instability (MSI) is also observed in 10-15% sporadic colorectal cancer (CRC), owing to the aberrant methylation of MLH1 promoter. MSI is not confined to only intergenic non-coding repeated sequences but also affects intronic and coding mononucleotide repeats (cMNR), leading to frameshift mutations in numerous genes (Mori et al., 2001; Duval and Hamelin, 2002; Suzuki et al., 2002; Woerner et al., 2003) . Until now, accumulation of such mutational events at genes containing cMNR is thought to be the major molecular mechanism by which MMR-deficient cells experience functional changes with putative oncogenic effects, defining the so-called mutator pathway. In absence of functional studies, several attempts have been made to discriminate between the genes that are true targets for colorectal MSI-driven mutagenesis, and the others whose mutations occur randomly, because of the structural or yet undefined criteria in the context of the high level of instability characterizing these tumours. A high mutation prevalence, a bi-allelic inactivation and a role in a growth suppressor pathway are among the most widely accepted criteria, but no consensus has been achieved, especially no mutation incidence cut-off value could be defined (Boland et al., 1998; Duval and Hamelin, 2002) . To overcome this problem, different statistical analyses independent of functional considerations have been proposed (Duval et al., 2001; Woerner et al., 2003) . Until now, they have been applied to the analyses of mutational data sets concerning target genes that belong to different signalling pathways with no direct relationship. As alterations of these genes could be of functional significance if associated with other mutations in the same pathway, owing to their synergistic effects, it seems of interest to take into consideration all possible target genes involved in closely related biological networks, as proposed previously (Suzuki et al., 2002) .
In the present study, we have exhaustively taken into consideration the presence of mutations in almost all genes containing cMNR covering the major DNA damage signalling and repair pathways. Based on this method, an overview of how MSI leads to genomic changes with putative synergistic effects in these pathways could be obtained.
Results

Patients and tumours
The clinicopathological characteristics of the patients and their tumours are reported in Table 1 . The comparison between the familial and the sporadic cases did not show any significant differences in any of the clinicopathological characteristics. Among the 31 familial cases, defects in MLH1 and MSH2 were observed in 15 and 10 cases, respectively (Table 1) .
Characterization of the mutations in genes involved in DNA damage signalling and repair pathways We have performed a systematic in silico search for genes containing an exonic mononucleotide repeat of at least eight bases (Ensembl release 32). We have studied 24 genes involved in base excision repair (BER), nucleotide excision repair (NER), MMR, double-strand break (DSB) repair or DNA damage signalling. Among them, seven had not been previously identified as potential target genes; four of them are involved in DNA damage signalling or metabolism (RIF1, TOPORS, TOPBP1 and SMC1L1) and three in replication, either in translesion synthesis (REV1L and REV3L, the polymerase zeta catalytic subunit) or as a PCNA-interacting subunit of polymerase d (POLD3). We further looked for mutations in the intronic MRE11 T11 tract because they impair the splicing process, resulting in a strong decrease of the MRE11 protein level (Giannini et al., 2002) . The presence of frameshift mutations is based on peak pattern alterations compared with the normal profile. Examples of representative chromatograms obtained for various genes and tumours are illustrated in Figure 1 . The presence of mutations located within the repeated sequence of the 25 selected genes is shown for each tumour in Figure 2 . MRE11 mutations have been found in the majority of colorectal MSI tumours (74%). Five genes (BRCA1, BRCA2, SMC1L1, TOPBP1 and TOPORS) were devoid of mutation and two (WRN and XRCC2) displayed a single mutation in our series of tumours. The number of mutations varied greatly among the tumours -one tumour (FK15) lacked mutations in these genes but carried mutations in TGFb-RII and TCF4, two well-known target genes in MSI CRC (data not shown). The range of mutated genes within the tumours varied from 0 to 12, with a median of five mutations per tumour.
Identification of the real-target genes according to the maximum likelihood method In order to identify the so-called real-target genes for instability, the mutation frequencies of the 24 cMNR were analysed using the statistical maximum likelihood method described previously (Duval et al., 2001) . The MRE11 gene whose mutations occur in a T11 intronic tract has been excluded from the statistical analysis because the consequences of MRE11 alterations are less clear than those of frameshift mutations. Yet, the extent of aberrant splicing increases with the size of the deletions at the MRE11 T11 tract, resulting in variable wild-type MRE11 expression. The likelihood method allowed us to individualize two groups of genes according to their mutation frequency with an observed cutoff value at 33%. The first group consisted of seven genes that are considered as real-targets for instability, shown as black histograms (Figure 3 ). This group included three already known target genes (RAD50, MSH6 and MSH3), as well as four additional genes that had not been studied previously (POLD3) or had not been definitely assigned as real-target genes (ATR, MBD4, DNA-PKcs). All other 17 genes represented the second group of genes that are unlikely to play a major individual role during MSI colorectal tumour progression ( Figure 3 , grey histograms).
Analysis of RAD50 and MRE11 protein expression in MSI CRC according to their mutational status
In order to assess how the mutations detected in the MRE11 genes affected MRE11 and RAD50 protein expression, we performed an immunohistochemical study on 28 of the 39 MSI cases on serial sections. In the normal colonic epithelium, MRE11 and RAD50 expression exhibited a strong ubiquitous nuclear immunostaining, as in the case of lymphocytes, endothelial cells and smooth muscle cells (Figure 4 ). Among the 28 tumours analysed, six were devoid of mutations in both MRE11 and RAD50 and displayed a strong and homogeneous immunostaining of both proteins. In the nine cases that displayed mutations in both MRE11 and RAD50, their expression was decreased in nine and seven cases, respectively (illustrated in Figure 4 ; case FK14). Among the 13 cases displaying a mutation in MRE11 only, we observed a clear loss of expression, with no or very faint staining in all or part of the tumour in 11 cases (illustrated in Figure 4 ; cases SK2, SK7). In two remaining cases (FK18 and FK23), no decrease in MRE11 expression could be detected, whatever tumour area was considered; FK18 retained a wild-type MRE11 allele associated with a mutation consisting in a 1 bp deletion, which has previously been reported to moderately affect MRE11 expression (Ottini et al., 2004) . As illustrated in Figure 4 , the expression of RAD50 fully overlapped that of MRE11, being undetectable or very faint in the tumour areas where MRE11 was either absent or very weak, in agreement with previous reports showing that mutations in MRE11 are associated with a reduced expression of the three members of the MRE11/ RAD50/NBS1 complex. Interestingly, we could also evaluate the expression of MRE11 and RAD50 in an adenoma derived from a patient (FK14) whose tumour had mutations in both genes (Figure 4 ). Although the adenoma displayed a mutation of MRE11 identical to that of the adenocarcinoma, it lacked the RAD50 mutation; the expression of both MRE11 and RAD50 was identical and lost in part of the adenoma, confirming further that a defect in MRE11 is sufficient to downregulate RAD50 and that it may be an early event in colorectal carcinogenesis (Figure 4) .
Analysis of cumulative mutation frequencies in the different genes involved in a given DNA damage signalling or repair pathway We further performed mutation analyses of the 24 selected genes with cMNR based on their involvement in a particular functional network to calculate the cumulative mutation frequencies, shown as dotted histograms (Figure 3) . We observed that the great majority of the tumours carried a mutation in at least one of the genes involved in MMR (82%) or in DNA damage signalling (74%). In comparison, the highest mutation rates observed for the genes analysed individually did not exceed 51% for the MMR MSH3 gene or 44% for the DNA damage signalling gene ATR. Similarly, DSB repair was affected in 59% of the tumours, whereas RAD50 and DNA-PKcs, the genes presenting the highest mutation rate in their coding repeated tract, were mutated in no more than 34% of the cases. The two error-prone polymerases capable of bypassing DNA lesions, REV1L and REV3L, were mutated in, respectively, five and four of the 39 MSI tumours; again, as no tumour had a concomitant mutation in these genes, translesion polymerases were targeted in 23% of Right  G1  T1  N0  M0  I  MLH1  FK2  38  M  Right  G1  T4  N0  M0  II  MSH2  FK3  65  F  Right  G2  T1  N0  M0  I  MSH2  MSH2  FK4  46  F  Left  Mucinous  T4  N1  M0  III  MSH2  FK5  65  F  Right  G1  T2  N0  M0  I  MLH1  MLH1  FK6  67  F  Right  G2  T3  N0  Mx  ND  MLH1  MLH1  FK7  27  M  Right  G1  T3  N0  M0  II  MLH1  MLH1  FK8  55  M  Right  G2  T4  N1  M1  IV  MLH1  FK9  42  M  Right  G1  T3  N2  M0  III  MLH1  FK10 52 G2  T2  N0  M0  I  FK25  38  M  Left  G1  T2  N0  M1  IV  FK26  37  M  Right  Mucinous  T3  N1  M0  III  FK27  59  F  Right  G1  T3  N0  M0  II  MLH1  MLH1  FK28  40  M  Right  G3  T4  N2  M0  III  MSH2  FK29  72  M  Right  Mucinous  T4  N0  M0  II  FK30  39  M  Right  G2  T3  N0  M0  II  MLH1  FK31  36  M  Right  G3  T3  N0  Mx  ND  MSH2  MSH2   Sporadic CRC  SK1  55  F  Right  G3  T3  N0  M0  II  SK2  66  M  Right  Mucinous  T3  N2  M0  III  SK3  41  M  Right  G3  T3  N0  M0  II  SK4  27  M  Rectum  G2  T3  N0  M0  II  SK5  54  F  Right  G3  T3  N1  M0  III  SK6  70  F  Right  G3  T4  N1  M0  III  SK7  51  F  Right  Adenocarcinoid  T4  Nx  M1  IV  SK8  48  M  Right  G2  T4  N2  M0  III Abbreviations: UICC, International Union Against Cancer; IHC, immunohistochemical; CRC, colorectal cancer; ND, not determined. The tumours were located either right (ascending and transverse colon) or left (descending and sigmoid colon) to the splenic flexure or in the rectum. The grading of differentiation was performed according to the WHO criteria; tumours were classified as mucinous when an area of extracellular mucin secretion was greater that 50%. Staging was based on tumour size (T), lymph node invasion (N) and distant metastasis (M), according to the classification defined by the UICC. Defects in MSH2 or MLH1 were defined for the familial cases either by immunohistochemical staining or through the determination of the germline mutation.
DNA damage response in MSI colorectal cancer C Miquel et al tumours. Thus, by using this approach, the presence of an abnormality in a given pathway was repeatedly twice as frequent than that of a particular gene participating in the pathway.
Discussion
Gene mutation frequency by itself may not be the only reliable criterion in the case of tumours with an exacerbated mutator phenotype, because the accumulation of mutations targeting several genes involved in a particular biological process may synergize and have significant functional consequences even when the mutation frequencies of genes taken independently are too low to be considered as real targets (Suzuki et al., 2002) . Thus, we here develop for the first time an exhaustive mutational analysis focused on 25 target genes containing cMNR covering the major DNA damage signalling and repair in a large series of MSI CRC, owing to the role of these processes in the control of the genome integrity and tumour sensitivity to chemotherapeutic agents. Our results show that DNA damage signalling, DSB repair and MMR are frequently altered in MSI CRC, whereas NER and BER pathways are seldom targeted. Interestingly, the role of DNA damage response as an anticancer barrier in early human tumorigenesis has recently been proposed (Bartkova et al., 2005) . Indeed, constitutive activation of the DNA damage response frequently occurs at preinvasive stages of major types of human tumours, including CRC, and this checkpoint response is believed to delay or prevent malignant transformation of early lesions (Bartkova et al., 2005) . By impairing cell-cycle arrest, senescence and apoptosis, mutations compromising the ATR/ATM-regulated DNA damage response network, such as those occurring in MSI CRC, may allow cell proliferation, survival and tumour progression (Bartkova et al., 2005) . Using the statistical maximum likelihood method designed to discriminate Real-Target genes from ByStander genes described previously (Duval et al., 2001 ), we further show that genes are divided into two groups that differ significantly in their respective mutation frequencies. Of interest, we observed that real-target genes are scattered over several major DNA repair pathways, which also comprise a number of ByStander genes that behave as additional potential targets for MSI-driven mutations (Figure 3 ). For example, DSB repair may be hampered because of mutations in RealTarget genes, such as DNA-PKcs or RAD50/MRE11, or in ByStander genes, like BLM or XRCC2. It is noteworthy that defects in any of the above-mentioned genes have been further implicated in hypersensitivity to bleomycin, a DSB inducer, or camptothecin, a topoisomerase I inhibitor (Li et al., 2004; Pommier, 2006; Takemura et al., 2006) . Interestingly, our results show that only a minority of MSI CRC is free from mutations in both MRE11 and RAD50 genes. We could further show by immunohistochemistry that mutations in either gene lead to concomitant lack of MRE11 and RAD50 expression in CRC, in keeping with the data obtained by Western blot showing that mutations in either gene result in a significantly decreased expression of the MRE11/RAD50/NBS1 complex (Giannini et al., 2004 (Giannini et al., , 2002 . Based on these observations, it is tempting to speculate that the increased chemosensitivity of MSI CRC to irinotecan, an analogue of camptothecin, may result from a defect in the MRE11/RAD50/NBS1 complex (Fallik et al., 2003) .
To our knowledge, our study is the first one to report that translesion polymerases, REV1L and REV3L, may be targeted in MSI CRC, although mutations occur at Figure 1 Examples of the detection of frameshift mutations in coding mononucleotide repeated sequences. The regions encompassing the repeated sequences were amplified by PCR using fluorescent primers and migrated on an ABI3100 genetic analyser (Applied Biosystems). The profiles were analysed using the GeneScan 3.2 software. The wild-type allele is shown in plain, and the mutated allele is indicated by an arrow.
DNA damage response in MSI colorectal cancer C Miquel et al rates below the cutoff value previously defined. Regarding the particular cases of genes believed to modulate the response to DNA damage-inducing drugs, their mutation rates need not be elevated to impair the clinical outcome, as mutations are likely to be selected upon treatment. Translesion polymerases play a unique role in maintaining the integrity of the genome particularly when damaged DNA needs to be replicated, their defect may thus be particularly deleterious in response to various chemotherapeutic agents. Yet, REV3L-deficient vertebrate cells are hypersensitive to methylating-agents, platinum-containing drugs and ionizing radiation (Sonoda et al., 2003) .
In addition to post-replicative repair, some MMR components play a direct role in DNA damage signalling, cell cycle checkpoint and apoptosis (Jacob and Praz, 2002; Yanamadala and Ljungman, 2003; Jiricny, 2006) . Thus, a defect in MMR may contribute to the particular sensitivity of MSI CRC to chemotherapy. In the future, defining which DNA repair pathways are functionally relevant to predict the response of MSI CRC to the treatment with chemotherapeutic drugs should be made easier by such an approach and represents a major achievement in the management of patients. Additional exhaustive studies investigating the genomic consequences of MSI-driven mutations accumulating in other pathways with an expected important role in tumour progression would be of interest as well.
Materials and methods
Tumour samples
Primary colon adenocarcinomas displaying MSI were obtained from 31 patients with familial history of colorectal cancer and eight sporadic cases. Specimens were collected following the Institutional Ethics Committee approval and French Medical Research Council guidelines. MSI was tested using the reference Bethesda panel and all were classified as MSI-high according to the National Cancer Institute recommendations (Boland et al., 1998) . The presence of a germline mutation in MSH2 or MLH1 has been established for 19 patients. The histologic type and the grading of differentiation were assessed according to the World Health Organization criteria. Tumour staging was determined according to the criteria defined by the World Health Organization and the International Union Against Cancer.
Immunohistochemistry
Immunohistochemistry for MSH2 and MLH1 was performed as previously described (Fallik et al., 2003) . Immunohistochemistry for MRE11 and RAD50 were performed on 4-mm sections from formalin-fixed, paraffin-embedded tissues Figure 3 Cumulative gene mutation frequencies according to the various DNA damage signalling and repair pathways. Histograms in black represent the mutation frequencies of genes identified as Real-Target genes using the maximum likelihood statistical method; other genes are shown in grey. Dotted histograms represent the cumulative mutation frequency obtained by taking into consideration the genes involved in a given pathway, for example DNA damage signalling, DSB repair, MMR and TLS. Figure 4 Immunohistochemical analysis of MRE11 and RAD50 in normal colonic mucosa and MSI colorectal tumours. Normal mucosa displays a strong nuclear MRE11 and RAD50 immunostaining. Adenocarcinomas carrying MRE11 mutations, with (FK14) or without (SK2 and SK7) RAD50 mutations, display a severe reduction or complete loss of expression of both proteins. The adenoma from patient FK14 that carries an MRE11 mutation only also shows loss of expression of both MRE11 and RAD50. Original magnification Â 20.
DNA damage response in MSI colorectal cancer C Miquel et al previously deparaffinized in xylene and rehydrated through a graded alcohol series to distilled water. Antigen retrieval was carried out by heating in a microwave oven for 20 min at 991C in 10 mM citrate buffer (pH 7.3). Then, endogenous peroxydase activity was blocked by immersion in 3% H 2 O 2 for 5 min. The sections were then incubated for 1 h at room temperature with a mouse monoclonal antibody against RAD50 (clone13B3/2C6, 1:50 dilution, GeneTex, San Antonio, TX, USA) or with a rabbit polyclonal antibodies against MRE11 (1:300, Novus Biologicals, Littleton, CO, USA). The immunoreactivity was revealed with the Dako EnVision system (Glostrup, Denmark) according to the manufacturer's instructions and using diaminobenzidine as chromogen. Sections were counterstained with hematoxylin and coverslipped for microscopic evaluation. Negative control staining was performed by omitting the primary antibody. In all cases analysed, the normal colon mucosa flanking the tumour tissue served as internal positive control. Only nuclear staining was taken into account. The MRE11 and RAD50 immunostaining patterns were assessed independently by two pathologists who were not aware of the mutation status.
DNA extraction
Genomic DNA was extracted from 7-mm-thick formol-fixed paraffin-embedded tissue sections as described (Fallik et al., 2003) . The level of contamination of tumours by normal cells has been estimated from the relative intensities of BAT-26 and BAT-25 mutated and normal profiles upon electrophoresis, as described (Brennetot et al., 2005) . Only two cases (FK23 and FK29) contained less than 40% tumour DNA that has been established to be the limit for an optimal detection of mutations in target genes (Brennetot et al., 2005) .
Detection of frameshift mutations
The regions encompassing the repeated sequences contained in the 25 selected genes were amplified either in monoplex or in multiplex polymerase chain reaction (PCR). PCR was carried out on approximately 50 ng genomic DNA using fluorescent primers and HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany), as described (Fallik et al., 2003) . Oligonucleotide sequences and protocol details are available upon request. The electrophoresis profiles of the PCR products were analysed using the GeneScan 3.2 software (Applied Biosystems, Foster City, CA, USA). The presence of frameshift mutations is based on peak pattern alterations compared with the reference peak size and profile patterns established for each gene using numerous normal DNA samples. All PCR with abnormal profiles were repeated at least twice in independent monoplex PCR to confirm the presence of a mutation.
Statistical analysis
Differences in the mean mutation frequency according to a number of clinicopathological parameters, including gender, tumour location, tumour stage and differentiation have been performed using the Epi6.1 software (World Health Organization). In order to discriminate between the real-target and the ByStander genes, we used the maximum likelihood method described previously (Duval et al., 2001 ).
